CARDIZEM Drug Patent Profile

Which patents cover Cardizem, and when can generic versions of Cardizem launch?

Cardizem is a drug marketed by Biovail, Biovail Labs Intl, and Bausch. and is included in six NDAs.

The generic ingredient in CARDIZEM is diltiazem hydrochloride. There are twenty-six drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the diltiazem hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cardizem

A generic version of CARDIZEM was approved as diltiazem hydrochloride by TEVA on May 31^st, 1995.

Summary for CARDIZEM

US Patents:	0
Applicants:	3
NDAs:	6

US Patents and Regulatory Information for CARDIZEM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biovail	CARDIZEM	diltiazem hydrochloride	INJECTABLE;INJECTION	020792-001	Sep 5, 1997		DISCN	No	No
Bausch	CARDIZEM LA	diltiazem hydrochloride	TABLET, EXTENDED RELEASE;ORAL	021392-006	Feb 6, 2003	AB	RX	Yes	Yes
Bausch	CARDIZEM	diltiazem hydrochloride	TABLET;ORAL	018602-004	Dec 8, 1986	AB	RX	Yes	Yes
Bausch	CARDIZEM	diltiazem hydrochloride	TABLET;ORAL	018602-001	Nov 5, 1982	AB	RX	Yes	No
Bausch	CARDIZEM CD	diltiazem hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	020062-005	Aug 24, 1999	AB3	RX	Yes	Yes
Biovail	CARDIZEM SR	diltiazem hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	019471-002	Jan 23, 1989		DISCN	Yes	No

International Patents for CARDIZEM

See the table below for patents covering CARDIZEM around the world.

Country	Patent Number	Title	Estimated Expiration
Germany	1443474
Denmark	126106
United Kingdom	1236467
Sweden	305870
Netherlands	141879
Switzerland	516587	Verfahren zur Herstellung von Benzothiazepinderivaten

CARDIZEM (Diltiazem Hydrochloride): Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

This analysis examines the investment potential, market environment, and financial outlook of CARDIZEM (diltiazem hydrochloride), a calcium channel blocker indicated primarily for angina pectoris, hypertension, and certain arrhythmias. The report covers current market data, regulatory landscape, patent status, competitive positioning, and future growth prospects to assist stakeholders in assessing risks and opportunities.

---

What Is the Current Market Profile of CARDIZEM?

Attribute	Details
Therapeutic Area	Cardiovascular (Angina, Hypertension, Arrhythmia)
Formulations	Oral tablets, sustained-release formulations, IV formulations
Global Sales (2022)	Estimated at $400 million (per IQVIA data)
Major Markets	United States, European Union, Japan, China
Estimated CAGR (2022–2027)	Approx. 3-4% (due to aging population, hypertension prevalence)

Sources: IQVIA, Pharma intelligence reports (2022–2023)

---

Market Dynamics Impacting Cardizem Investment

1. Patent and Generic Competition

• Patent Status: The original patents for Cardizem expired in the early 2000s in key jurisdictions, leading to widespread generic entry.
• Generic Landscape: Multiple manufacturers produce bioequivalent versions with narrow price margins.
• Implication: Margins for innovator drug sales have significantly decreased; future growth relies increasingly on branded formulations with differentiated delivery systems.

2. Regulatory Environment

• FDA and EMA Approvals: Established standards, but recent focus on biosimilar and generic approvals affecting market share.
• Emerging Markets: Increasing approvals in China and India, expanding the market size but intensifying generic competition.

3. Pricing Policies and Reimbursement

Region	Reimbursement Policy	Impact
United States	Evolving, leaning towards value-based pricing	Pressures on profit margins
European Union	Price controls vary by country	Limits on pricing flexibility
Emerging Markets	Price-sensitive, high generic penetration	Maximize volume over margins

Sources: OECD, European Medicines Agency, US CMS guidelines (2022)

4. Demographic and Disease Trends

Trend	Data	Effect on Market
Aging Population	>60 age group projections rising 20% globally (WHO, 2023)	Increased hypertension, angina cases
Hypertension Prevalence	~30% worldwide (WHO, 2023)	Steady demand for antihypertensive drugs
Cardiovascular Disease (CVD)	Leading cause of death (~17.9 million deaths/year, WHO 2023)	Sustained market need

---

Financial Trajectory and Investment Outlook for Cardizem

Historical Financial Performance

Year	Global Sales (Million USD)	CAGR (2018–2022)	Key Factors
2018	380	N/A	Established generic presence
2019	385	1.3%	Slight growth, increased market penetration
2020	390	1.3%	Impact of COVID-19, but resilient sales
2021	395	1.3%	Steady demand
2022	400	1.3%	Mature market, marginal growth

Note: Consistent low single-digit growth indicates limited upside without innovation.

Future Growth Drivers

Driver	Description	Expected Impact
Formulation Innovation	Development of extended-release, combination, or biosimilar formulations	Potential for premium pricing/market share
New Indications	Exploration of cardioprotective roles in other cardiovascular conditions	Expansion of market applications
Geographic Expansion	Penetration in emerging markets with large populations	Volume-driven growth
Digital Health Integration	Use of telemedicine, adherence monitoring improves prescribing trends	Market expansion, patient management

Investment Risks

Risk Factor	Description	Mitigation Strategies
Patent Expiry	Loss of exclusivity reduces margins	Focus on formulation differentiation, lifecycle management
Generic Competition	Price erosion and margin compression	Innovate with proprietary delivery systems
Regulatory Changes	Price controls, reimbursement shifts	Engage in policy dialogue, strategic pricing
Market Saturation	Mature markets with low growth	Expand into emerging markets

Competitive Landscape and Differentiation

Competitor	Product Name / Formulation	Market Share	Differentiation Strategies
Teva, Mylan (Generics)	Diltiazem Hydrochloride Tablets	~60% (global)	Price competition, bioequivalent copies
Novartis	Cardizem CD (Extended-release)	Limited	Proprietary extended-release formulations
Other Branded Players	Cardizem LA, Cardizem SR	Limited	Formulation innovations, dosing convenience

Note: Branded players face pressure from generics but may maintain some premium through formulation differentiation.

---

Market Outlook and Strategic Recommendations

Aspect	Commentary	Actionable Insights
Growth Potential	Moderate, driven by demographic trends and formulation innovation	Invest in R&D for novel formulations and delivery systems
Pricing Strategy	Focus on value-added formulations to maintain margins	Prioritize differentiated offerings in mature markets
Geographic Expansion	High potential in emerging markets with rising CVD burden	Enter or expand in China, India, Southeast Asia
Regulatory Navigation	Prepare for evolving reimbursement policies	Engage early with regulators, adapt pricing models
Lifecycle Management	Develop New Molecular Entities, Biosimilars	Diversify portfolio, extend product lifecycle

---

Key Takeaways

• Market Maturity: Cardizem's mature market landscape results in stable but slow growth, primarily driven by demographic trends.
• Competitive Pressure: Widespread generic presence limits profit margins; differentiation through innovative formulations remains critical.
• Growth Opportunities: Emerging markets, formulation innovation, and extension of indications are key avenues for growth.
• Regulatory Factors: Price controls and reimbursement policies require strategic engagement; biosimilar and generic entrants pose ongoing threats.
• Investment Strategy: Focus on diversified formulations, geographic expansion, and lifecycle management to optimize returns.

---

FAQs

1. What are the main drivers affecting Cardizem sales?
Demographic aging, rising hypertension and CVD prevalence, generic competition, and formulation innovations primarily influence sales dynamics.

2. How does patent expiration impact the market for Cardizem?
Patent expiration facilitated generic entry, driving prices down and compressing margins, reducing profitability for original manufacturers.

3. Which geographic markets offer the most growth potential?
Emerging markets such as China, India, and Southeast Asia present significant expansion opportunities due to increasing disease burden and less market saturation.

4. What strategies can companies employ to maintain profitability?
Differentiation through proprietary formulations, expanding indications, local market penetration, and lifecycle management are key strategies.

5. How might regulatory changes affect future investment?
Price controls, reimbursement reforms, and approval pathways for biosimilars or generics can influence market access and margins.

---

References

[1] IQVIA. (2023). Global Pharmaceutical Market Data.
[2] WHO. (2023). Cardiovascular Disease Statistics.
[3] OECD. (2023). Health Policy Watch: Cardiology Drugs.
[4] European Medicines Agency. (2022). Pharmacovigilance and Market Authorization.
[5] US Centers for Medicare & Medicaid Services. (2022). Drug Reimbursement Policies.

---

This analysis aims to assist investors and corporate decision-makers in evaluating the strategic landscape of Cardizem in the current pharmaceutical environment.